Literature DB >> 24677208

Bortezomib plus melphalan and prednisone (VMP regimen) as the initial treatment for IgE multiple myeloma: a case study.

Hiroyuki Sato1, Yusuke Komiya, Shigeru Hoshino.   

Abstract

Patients with IgE multiple myeloma have poor prognosis. Due to the rarity of this condition, no standard treatment has been developed. As the VMP regimen (bortezomib plus melphalan and prednisone) has been reported to be highly effective in the treatment of other types of myeloma, we treated a patient with newly diagnosed IgE myeloma using the VMP regimen. Her myeloma responded well to VMP regimen. The results of this case report thus suggest that physicians may consider VMP regimen for use as the initial treatment for IgE myeloma.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24677208     DOI： 10.1007/s12185-014-1571-5

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  24 in total

1.  A case of IgE multiple myeloma.

Authors:  Lyn Lloyd; Sandra L Klingberg; Mere Kende; Jillian F Howell; Alan E Clague
Journal:  Pathology       Date:  2003-02       Impact factor: 5.306

2.  Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants.

Authors:  Hervé Avet-Loiseau; Richard Garand; Laurence Lodé; Jean-Luc Harousseau; Régis Bataille
Journal:  Blood       Date:  2002-10-03       Impact factor: 22.113

3.  A case of IgE-multiple myeloma presenting with a high serum Krebs von den Lungen-6 level.

Authors:  Jian Hua; Masao Hagihara; Morihiro Inoue; Yasunobu Iwaki
Journal:  Leuk Res       Date:  2012-03-14       Impact factor: 3.156

4.  IgE-type multiple myeloma with the late development of IgA2 kappa and plasma cell leukaemia.

Authors:  Weldon Chiu; Humphrey Pullon; See-Tarn Woon; Paul Oei; Roy The; Rohan Ameratunga
Journal:  Pathology       Date:  2010-01       Impact factor: 5.306

Review 5.  IgE myeloma: a case presentation and a review of the literature.

Authors:  K J Kairemo; M Lindberg; M Prytz
Journal:  Scand J Clin Lab Invest       Date:  1999-10       Impact factor: 1.713

6.  Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.

Authors:  Antonio Palumbo; Sara Bringhen; Alessandra Larocca; Davide Rossi; Francesco Di Raimondo; Valeria Magarotto; Francesca Patriarca; Anna Levi; Giulia Benevolo; Iolanda Donatella Vincelli; Mariella Grasso; Luca Franceschini; Daniela Gottardi; Renato Zambello; Vittorio Montefusco; Antonietta Pia Falcone; Paola Omedé; Roberto Marasca; Fortunato Morabito; Roberto Mina; Tommasina Guglielmelli; Chiara Nozzoli; Roberto Passera; Gianluca Gaidano; Massimo Offidani; Roberto Ria; Maria Teresa Petrucci; Pellegrino Musto; Mario Boccadoro; Michele Cavo
Journal:  J Clin Oncol       Date:  2014-01-21       Impact factor: 44.544

7.  A new case of IgE myeloma.

Authors:  F Invernizzi; G Monti; A G Caviglia; P Meroni; C Zanussi
Journal:  Acta Haematol       Date:  1991       Impact factor: 2.195

8.  Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

Authors:  Sara Bringhen; Alessandra Larocca; Davide Rossi; Maide Cavalli; Mariella Genuardi; Roberto Ria; Silvia Gentili; Francesca Patriarca; Chiara Nozzoli; Anna Levi; Tommasina Guglielmelli; Giulia Benevolo; Vincenzo Callea; Vincenzo Rizzo; Clotilde Cangialosi; Pellegrino Musto; Luca De Rosa; Anna Marina Liberati; Mariella Grasso; Antonietta P Falcone; Andrea Evangelista; Michele Cavo; Gianluca Gaidano; Mario Boccadoro; Antonio Palumbo
Journal:  Blood       Date:  2010-08-31       Impact factor: 22.113

9.  Prozone effect of serum IgE levels in a case of plasma cell leukemia.

Authors:  Giampaolo Talamo; William Castellani; Nathan G Dolloff
Journal:  J Hematol Oncol       Date:  2010-09-10       Impact factor: 17.388

10.  A new case of IgE myeloma.

Authors:  R L Alexander; S T Roodman; P J Petruska; C C Tsai; C G Janney
Journal:  Clin Chem       Date:  1992-11       Impact factor: 8.327
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.